Brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post earnings of ($0.16) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.12). Pieris Pharmaceuticals reported earnings per share of $0.17 during the same quarter last year, which suggests a negative year-over-year growth rate of 194.1%. The firm is expected to report its next earnings report on Friday, March 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.45) per share for the current year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the business will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.07) to ($0.62). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%.
In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy acquired 5,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was acquired at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.07% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its stake in Pieris Pharmaceuticals by 49.1% in the 2nd quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after purchasing an additional 884,348 shares in the last quarter. Acadian Asset Management LLC raised its stake in Pieris Pharmaceuticals by 2.0% in the 3rd quarter. Acadian Asset Management LLC now owns 2,167,227 shares of the biotechnology company’s stock worth $12,136,000 after purchasing an additional 42,354 shares in the last quarter. Aquilo Capital Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $10,013,000. Prosight Management LP increased its holdings in Pieris Pharmaceuticals by 22.2% in the 3rd quarter. Prosight Management LP now owns 1,661,940 shares of the biotechnology company’s stock valued at $9,307,000 after buying an additional 301,940 shares during the period. Finally, Sphera Funds Management LTD. increased its holdings in Pieris Pharmaceuticals by 7.4% in the 3rd quarter. Sphera Funds Management LTD. now owns 904,686 shares of the biotechnology company’s stock valued at $5,066,000 after buying an additional 62,054 shares during the period. Institutional investors and hedge funds own 65.36% of the company’s stock.
Shares of NASDAQ PIRS remained flat at $$3.51 during mid-day trading on Monday. 428,334 shares of the stock were exchanged, compared to its average volume of 569,235. The firm has a market cap of $190.07 million, a PE ratio of -8.78 and a beta of 1.88. Pieris Pharmaceuticals has a one year low of $3.04 and a one year high of $9.75.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.